Original Research J Clin Psychiatry October 2023

Solriamfetol for Attention-Deficit/Hyperactivity Disorder in Adults: A Double-Blind Placebo-Controlled Pilot Study

JCP 2023;84(6):10.4088/JCP.23m14934

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2023;84(6):10.4088/JCP.23m14934 Clinical Summary Many adults with attention-deficit/hyperactivity disorder still have meaningful symptoms or executive dysfunction despite available medications, and some cannot tolerate standard options. This pilot trial tests whether solriamfetol, a dopamine and norepinephrine reuptake inhibitor already approved for sleepiness disorders, can provide a clinically useful alternative for adult ADHD. FAQ Did solriamfetol improve ADHD symptoms in adults in this study? 12 questions
Key Takeaways Separation from placebo on clinician-rated ADHD symptoms emerged by week 3, with an AISRS mean difference of −3.4 (95% CI, −6.7 to −0.1; P = .0439), and reached −4.3 (95% CI, −7.7 to −1.0; P = .0106) by week 6. 5 takeaways Clinical Guide How do clinicians identify which adults with ADHD are appropriate candidates for off-label solriamfetol treatment? 6 steps Clinical Guide How should clinicians dose-optimize and monitor solriamfetol for adults with ADHD based on this pilot study? 9 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe